Lack of evidence for neonatal misoprostol neurodevelopmental toxicity in C57BL6/J mice

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Koenig, Claire M ^a   Walker, Cheryl K ^a,b   Qi, Lihong ^a   Pessah, Isaac N ^a   Berman, Robert F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL;

ANIMAL EXPERIMENT; ANIMAL HOUSING; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTISM; BODY GROWTH; C57BL 6 MOUSE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DRUG DOSE COMPARISON; EXPERIMENTAL TEST; FEMALE; LEARNING; LOCOMOTION; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOTOR DEVELOPMENT; MOUSE; NEUROTOXICITY; NEWBORN; NONHUMAN; PERINATAL PERIOD; PREPULSE INHIBITION; REFLEX; SENSORY SYSTEM; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIALIZATION; SPATIAL MEMORY; STEREOTYPY; VOCALIZATION; WEANING;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ANIMALS; BEHAVIOR, ANIMAL; FEMALE; MATERNAL EXPOSURE; MICE; MICE, INBRED C57BL; MISOPROSTOL; PREGNANCY;

EID: 84862174194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038911     Document Type: Article

References (77)

1. Fombonne E, (1999) The epidemiology of autism: a review. Psychol Med 29: 769-786.
2. Chakrabarti S, Fombonne E, (2001) Pervasive developmental disorders in preschool children. JAMA 285: 3093-3099.
3. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, et al. (2001) Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 108: 1155-1161.
4. Hertz-Picciotto I, Delwiche L, (2009) The rise in autism and the role of age at diagnosis. Epidemiology 20: 84-90.
5. Gardener H, Spiegelman D, Buka SL, (2011) Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics 128: 344-355.
6. Rice C, Nicholas J, Baio J, Pettygrove S, Lee LC, et al. (2010) Changes in autism spectrum disorder prevalence in 4 areas of the United States. Disabil Health J 3: 186-201.
7. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, et al. (2011) Genetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism. Arch Gen Psychiatry.
8. Pessah IN, Seegal RF, Lein PJ, LaSalle J, Yee BK, et al. (2008) Immunologic and neurodevelopmental susceptibilities of autism. Neurotoxicology 29: 532-545.
9. Lawler CP, Croen LA, Grether JK, Van de Water J, (2004) Identifying environmental contributions to autism: provocative clues and false leads. Ment Retard Dev Disabil Res Rev 10: 292-302.
10. Landrigan PJ, (2010) What causes autism? Exploring the environmental contribution. Curr Opin Pediatr 22: 219-225.
11. Volk HE, Hertz-Picciotto I, Delwiche L, Lurmann F, McConnell R, (2011) Residential proximity to freeways and autism in the CHARGE study. Environ Health Perspect 119: 873-877.
12. Sullivan KM, (2008) The interaction of agricultural pesticides and marginal iodine nutrition status as a cause of autism spectrum disorders. Environ Health Perspect 116: A155.
13. McGovern V, (2007) Autism and agricultural pesticides. Integrating data to track trends. Environ Health Perspect 115: A504.
14. Schmidt RJ, Hansen RL, Hartiala J, Allayee H, Schmidt LC, et al. (2011) Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. Epidemiology 22: 476-485.
15. Beard CM, Panser LA, Katusic SK, (2011) Is excess folic acid supplementation a risk factor for autism? Med Hypotheses 77: 15-17.
16. Hultman CM, Sandin S, Levine SZ, Lichtenstein P, Reichenberg A, (2010) Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry.
17. Reichenberg A, Gross R, Sandin S, Susser ES, (2010) Advancing paternal and maternal age are both important for autism risk. Am J Public Health 100: 772-773; author reply 773.
18. Croen LA, Najjar DV, Fireman B, Grether JK, (2007) Maternal and paternal age and risk of autism spectrum disorders. Arch Pediatr Adolesc Med 161: 334-340.
19. Evatt ML, DeLong MR, Grant WB, Cannell JJ, Tangpricha V, (2009) Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 73: 997.
20. Curran MP, (2011) Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. Paediatr Drugs 13: 197-204.
21. Bell J, Abdul-Rahman O, Buttross S, (2011) Autism and vaccines: search for cause amidst controversy. J Miss State Med Assoc 52: 35-38.
22. Bandim JM, Ventura LO, Miller MT, Almeida HC, Costa AE, (2003) Autism and Mobius sequence: an exploratory study of children in northeastern Brazil. Arq Neuropsiquiatr 61: 181-185.
23. Miller MT, Ventura L, Stromland K, (2009) Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected. Birth Defects Res A Clin Mol Teratol 85: 667-676.
24. Pottie K, (1999) Is misoprostol teratogenic? Misoprostol use during early pregnancy and its association with Mobius' syndrome. Can Fam Physician 45: 315-316.
25. Williams PG, Hersh JH, (1997) A male with fetal valproate syndrome and autism. Dev Med Child Neurol 39: 632-634.
26. Williams G, King J, Cunningham M, Stephan M, Kerr B, et al. (2001) Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 43: 202-206.
27. Witter FR, (2011) Does treatment of premature labor with terbutaline increase the risk of autism spectrum disorders? Am J Obstet Gynecol.
28. Borbe HO, Niebch G, Nickel B, (1990) Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat. J Neural Transm pp. 131-137.
29. Silverstein FE, (1998) Improving the gastrointestinal safety of NSAIDs: the development of misoprostol-from hypothesis to clinical practice. Dig Dis Sci 43: 447-458.
30. Wong VW, Chan FK, (2005) Review: misoprostol or COX-2-specific or selective NSAIDs reduce gastrointestinal complications and symptomatic ulcers. ACP J Club 142: 75.
31. Shield MJ, (1992) Misoprostol: new frontiers; benefits beyond the gastrointestinal tract. Scand J Rheumatol pp. 31-52.
32. Enoch J, (1999) Misoprostol (Cytotec): a new method of inducing labor. Midwifery Today Int Midwife pp. 22-30.
33. Wing DA, (1999) Labor induction with misoprostol. Am J Obstet Gynecol 181: 339-345.
34. Stromland K, Sjogreen L, Miller M, Gillberg C, Wentz E, et al. (2002) Mobius sequence-a Swedish multidiscipline study. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 6: 35-45.
35. Gillberg C, Wing L, (1999) Autism: not an extremely rare disorder. Acta Psychiatr Scand 99: 399-406.
36. Dufour-Rainfray D, Vourc'h P, Tourlet S, Guilloteau D, Chalon S, et al. (2011) Fetal exposure to teratogens: evidence of genes involved in autism. Neurosci Biobehav Rev 35: 1254-1265.
37. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82: 477-488.
38. Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, et al. (2007) Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 39: 319-328.
39. Tamiji J, Crawford DA, (2010) Prostaglandin E(2) and misoprostol induce neurite retraction in Neuro-2a cells. Biochem Biophys Res Commun 398: 450-456.
40. Tamiji J, Crawford DA, (2010) Misoprostol elevates intracellular calcium in Neuro-2a cells via protein kinase A. Biochem Biophys Res Commun 399: 565-570.
41. Haynes DR, Whitehouse MW, Vernon-Roberts B, (1992) The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. Immunology 76: 251-257.
42. Dendorfer U, Oettgen P, Libermann TA, (1994) Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 14: 4443-4454.
43. Rus V, Nguyen P, Chevrier M, Stair R, Via CS, (1995) Preliminary Studies of in vitro and in vivo Effects of Misoprostol on Th-1 and Th-2 Cytokine Production. Am J Ther 2: 911-916.
44. Parker CW, Huber MG, Godt SM, (1995) Suppression of IL-4 Production in Murine Lymphocytes by Orally Effective Prostaglandin E(1) Analogs. Am J Ther 2: 772-776.
45. Larson SJ, (2002) Behavioral and motivational effects of immune-system activation. J Gen Psychol 129: 401-414.
46. Mehler MF, Kessler JA, (1998) Cytokines in brain development and function. Adv Protein Chem 52: 223-251.
47. Steinman L, (2004) Elaborate interactions between the immune and nervous systems. Nat Immunol 5: 575-581.
48. Ashwood P, Van de Water J, (2004) A review of autism and the immune response. Clin Dev Immunol 11: 165-174.
49. Ashwood P, Wills S, Van de Water J, (2006) The immune response in autism: a new frontier for autism research. J Leukoc Biol 80: 1-15.
50. Suzuki K, Matsuzaki H, Iwata K, Kameno Y, Shimmura C, et al. (2011) Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One 6: e20470.
51. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, et al. (2011) Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 25: 40-45.
52. Walker CK KP, Hansen RL, Hertz-Picciotto I. (May, 2008) Induction and augmentation of labor and autism. 7th Annual International Meeting for Autism Research, Oral Presentation.
53. Wing DA, Powers BL, Rayburn WF, (2008) Determining dose and endpoints of a controlled-release misoprostol vaginal insert for a phase III trial. J Reprod Med 53: 695-696.
54. Nuthalapaty FS, Ramsey PS, Biggio JR, Owen J, (2005) High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am J Obstet Gynecol 193: 1065-1070.
55. Rice D, Barone S Jr, (2000) Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108: 511-533.
56. Moy SS, Nadler JJ, Young NB, Perez A, Holloway LP, et al. (2007) Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behavioural brain research 176: 4-20.
57. Crawley JN, Paylor R, (1997) A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 31: 197-211.
58. Yang M, Scattoni ML, Zhodzishsky V, Chen T, Caldwell H, et al. (2007) Social approach behaviors are similar on conventional versus reverse lighting cycles, and in replications across cohorts, in BTBR T+ tf/J, C57BL/6J, and vasopressin receptor 1B mutant mice. Frontiers in behavioral neuroscience 1: 1.
59. Kovacs Z, Czurko A, Kekesi KA, Juhasz G, (2011) The effect of intraperitoneally administered dimethyl sulfoxide on absence-like epileptic activity of freely moving WAG/Rij rats. Journal of neuroscience methods 197: 133-136.
60. Di Giorgio AM, Hou Y, Zhao X, Zhang B, Lyeth BG, et al. (2008) Dimethyl sulfoxide provides neuroprotection in a traumatic brain injury model. Restorative neurology and neuroscience 26: 501-507.
61. Wahlsten D, (1974) A developmental time scale for postnatal changes in brain and behavior of B6D2F2 mice. Brain Res 72: 251-264.
62. Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, et al. (2004) Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 3: 287-302.
63. Jaubert PJ, Golub MS, Lo YY, Germann SL, Dehoff MH, et al. (2007) Complex, multimodal behavioral profile of the Homer1 knockout mouse. Genes Brain Behav 6: 141-154.
64. Irvine EE, Cheeta S, File SE, (2001) Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol Biochem Behav 68: 319-325.
65. Lister RG, (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92: 180-185.
66. Dulawa SC, Geyer MA, (2000) Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology 39: 2170-2179.
67. Graham FK, (1975) Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 12: 238-248.
68. Walsh TJ, Emerich DF, (1988) The hippocampus as a common target of neurotoxic agents. Toxicology 49: 137-140.
69. Paxinos G, Franklin KBJ, (2001) The Mouse Brain in Sterotaxic Coordinates, 2nd Edition. Academic Press, London, UK: Elsevier Science.
70. Choi EJ, Han JH, Lee CS, (2008) Prostaglandin analogue misoprostol attenuates neurotoxin 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death in differentiated PC12 cells. Brain research bulletin 77: 293-300.
71. Li J, Liang X, Wang Q, Breyer RM, McCullough L, et al. (2008) Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neuroscience letters 438: 210-215.
72. Lim SP, Andrews FJ, O'Brien PE, (1994) Misoprostol protection against acetaminophen-induced hepatotoxicity in the rat. Digestive diseases and sciences 39: 1249-1256.
73. Miller RC, LaNasa P, Hanson WR, (1994) Misoprostol-induced radioprotection of Syrian hamster embryo cells in utero from cell death and oncogenic transformation. Radiation research 139: 109-114.
74. Meyer U, Yee BK, Feldon J, (2007) The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist 13: 241-256.
75. LePage KT, Dickey RW, Gerwick WH, Jester EL, Murray TF, (2005) On the use of neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies. Critical reviews in neurobiology 17: 27-50.
76. Taniguchi H, Anacker C, Suarez-Mier GB, Wang Q, Andreasson K, (2011) Function of prostaglandin E2 EP receptors in the acute outcome of rodent hypoxic ischemic encephalopathy. Neuroscience letters 504: 185-190.
77. Johansson M, Wentz E, Fernell E, Stromland K, Miller MT, et al. (2001) Autistic spectrum disorders in Mobius sequence: a comprehensive study of 25 individuals. Dev Med Child Neurol 43: 338-345.